Article Details
Retrieved on: 2025-03-15 10:11:41
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Unity Biotechnology's Phase 2b ASPIRE study evaluating foselutoclax's efficacy against aflibercept for diabetic macular edema. It highlights the primary outcome measured in microns and mentions anti-VEGF treatment relevance. Tags such as Anirvan Ghosh, Sanofi, and biotechnology connect broadly to angiogenesis inhibitors and intravitreal injections.
Article found on: www.ophthalmologytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here